<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609853</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00085652</org_study_id>
    <secondary_id>R01DA043475</secondary_id>
    <nct_id>NCT03609853</nct_id>
  </id_info>
  <brief_title>Behavioral Pharmacology of THC and D-limonene</brief_title>
  <official_title>Behavioral Pharmacology of THC and D-limonene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized d-limonene
      and THC administered via inhalation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research
      Unit (BPRU). Participants will complete 9 acute drug administration periods in which they
      will administer THC alone, limonene alone, THC and limonene together, or placebo. Subjective
      drug effects and vital signs will be assessed following drug administration. Each participant
      will receive all 9 dose conditions in a randomized order using a placebo controlled
      within-subject crossover design. The study will help us understand the individual and
      interactive effects of THC and d-limonene, two common constituents found in cannabis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>placebo controlled, double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Anxiety as assessed by the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak rating (0-100) of Anxiety on the DEQ, a visual analog scale (VAS) self-report questionnaire with 0 being No anxiety and 100 being maximum anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Unpleasant Effect as assessed by the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak rating (0-100) of Unpleasant Effect on the DEQ, with 0 being no unpleasant effect and 100 being worst unpleasant effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difficulty in Performing Routine Tasks as assessed the Drug Effect Questionnaire (DEQ)</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak rating (0-100) of Difficulty Performing Routine Tasks on the DEQ, 0 being no difficulty and 100 being inability to perform task all together</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Rate</measure>
    <time_frame>6 hours</time_frame>
    <description>Peak change from baseline in Heart Rate (bpm) measured in seated position by automated monitor</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>D-limonene and THC Pharmacodynamics</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (5mL distilled water)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized low THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of pure THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized high THC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of pure THC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized low d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporized high d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low THC and low d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of THC paired with 1mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High THC and low d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of THC paired with 1mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low THC and high d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg of THC paired with 5mg of d-limonene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High THC and high d-limonene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg of THC paired with 5mg of d-limonene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo vapor (distilled water)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaporized THC, limonene, or THC and limonene</intervention_name>
    <description>Acute drug exposure</description>
    <arm_group_label>High THC and high d-limonene</arm_group_label>
    <arm_group_label>High THC and low d-limonene</arm_group_label>
    <arm_group_label>Low THC and high d-limonene</arm_group_label>
    <arm_group_label>Low THC and low d-limonene</arm_group_label>
    <arm_group_label>Vaporized high THC</arm_group_label>
    <arm_group_label>Vaporized high d-limonene</arm_group_label>
    <arm_group_label>Vaporized low THC</arm_group_label>
    <arm_group_label>Vaporized low d-limonene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have provided written informed consent

          2. Be between the ages of 18 and 55

          3. Be in good general health based on a physical examination, medical history, vital
             signs, 12-lead ECG and screening urine and blood tests

          4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the
             screening visit and at clinic admission

          5. Not be pregnant or nursing (if female). All females must have a negative serum
             pregnancy test at the screening visit and a negative urine pregnancy test at clinic
             admission.

          6. Have a body mass index (BMI) in the range of 18 to 36 kg/m2

          7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of
             150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg

          8. Have no allergies to any of the ingredients used to prepare vapor (THC, d-limonene).

          9. Report having experienced anxiety after consuming cannabis in the past.

        Exclusion Criteria:

          1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3
             month prior to the Screening Visit;

          2. History of or current evidence of significant medical (e.g. seizure disorder) or
             psychiatric illness (e.g. psychosis) judged by the investigator to put the participant
             at greater risk of experiencing an adverse event due to exposure or completion of
             other study procedures.

          3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within
             14 days of experimental sessions; which, in the opinion of the investigator or
             sponsor, will interfere with the study result or the safety of the subject.

          4. Use of a prescription medication (with the exception of birth control prescriptions)
             within 14 days of experimental sessions; which, in the opinion of the investigator or
             sponsor, will interfere with the study result or the safety of the subject.

          5. Use of dronabinol (MarinolÂ®) within the past month.

          6. Average use of cannabis more than 2 times per week in the prior 3 months.

          7. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g.,
             Prinzmetal's angina).

          8. Abnormal EKG result that in the investigator's opinion is clinically significant.

          9. Enrolled in another clinical trial or have received any drug as part of a research
             study within 30 days prior to dosing.

         10. Having previously sought medical attention to manage adverse effects following acute
             cannabis use.

         11. Individuals with anemia or who have donated blood in the prior 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua Elmore</last_name>
    <phone>410-550-9491</phone>
    <email>jelmore4@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Vandrey</last_name>
    </contact>
    <investigator>
      <last_name>Ryan Vandrey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

